- Home
- KRP vs GPCR Comparison
KRP vs GPCR Comparison
Compare KRP & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- GPCR
- Stock Information
- Founded
- KRP 2013
- GPCR 2016
- Country
- KRP United States
- GPCR United States
- Employees
- KRP N/A
- GPCR N/A
- Industry
- KRP Oil & Gas Production
- GPCR
- Sector
- KRP Energy
- GPCR
- Exchange
- KRP Nasdaq
- GPCR Nasdaq
- Market Cap
- KRP 1.4B
- GPCR 1.6B
- IPO Year
- KRP 2017
- GPCR 2023
- Fundamental
- Price
- KRP $15.78
- GPCR $23.77
- Analyst Decision
- KRP Buy
- GPCR Strong Buy
- Analyst Count
- KRP 4
- GPCR 7
- Target Price
- KRP $20.25
- GPCR $81.29
- AVG Volume (30 Days)
- KRP 724.0K
- GPCR 752.3K
- Earning Date
- KRP 02-27-2025
- GPCR 03-07-2025
- Dividend Yield
- KRP 11.09%
- GPCR N/A
- EPS Growth
- KRP N/A
- GPCR N/A
- EPS
- KRP 0.52
- GPCR N/A
- Revenue
- KRP $325,011,605.00
- GPCR N/A
- Revenue This Year
- KRP $17.70
- GPCR N/A
- Revenue Next Year
- KRP $13.07
- GPCR N/A
- P/E Ratio
- KRP $30.35
- GPCR N/A
- Revenue Growth
- KRP 30.47
- GPCR N/A
- 52 Week Low
- KRP $14.95
- GPCR $22.33
- 52 Week High
- KRP $17.07
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- KRP 53.43
- GPCR 37.89
- Support Level
- KRP $15.31
- GPCR $22.33
- Resistance Level
- KRP $15.98
- GPCR $25.17
- Average True Range (ATR)
- KRP 0.23
- GPCR 1.73
- MACD
- KRP 0.06
- GPCR -0.37
- Stochastic Oscillator
- KRP 74.68
- GPCR 15.94
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.